GALE-based drug design strategies may include enzyme activity modulators, allosteric regulators, or metabolic pathway redirectors, potentially developing next-generation atopic dermatitis therapeutics with reduced side effects and enhanced targeting specificity. The gene discussed is GALE; the disease is atopic eczema.